Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Extragonadal Germ Cell Tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Extragonadal Germ Cell Tumor. Displaying page 1 of 1.
    EudraCT Number: 2004-000405-22 Sponsor Protocol Number: TE23 Start Date*: 2005-02-25
    Sponsor Name:Medical Research Council
    Full Title: TE23: Randomised Phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP chemotherapy in poor prognosis male germ cell tumours.
    Medical condition: Poor prognosis male germ cell tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043333 Testicular germ cell tumour mixed stage III LLT
    9.1 10015802 Extragonadal primary germ cell tumour mixed stage III LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005095-28 Sponsor Protocol Number: IRST186.02 Start Date*: 2015-04-16
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Olaparib as salvage treatment for cisplatin-resistant germ cell tumor.
    Medical condition: cisplatin-resistant germ cell tumor
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015400-26 Sponsor Protocol Number: ARQ 197-A-U251 Start Date*: 2010-03-04
    Sponsor Name:Daiichi Sankyo Pharma Development
    Full Title: MULTICENTER PHASE 2 TRIAL OF ARQ 197 FOR SUBJECTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS
    Medical condition: Germ cell tumors (GCT) including testicular and non-central nervous system (non-CNS) extragonadal types.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10061184 Germ cell cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000589-31 Sponsor Protocol Number: NEMESIS Start Date*: 2018-02-02
    Sponsor Name:SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA
    Full Title: multi stage phase II trial of Nivolumab (an anti –PD-1) in patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Medical condition: patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004418-32 Sponsor Protocol Number: TestisCAB Start Date*: 2016-03-16
    Sponsor Name:Oslo University Hospital - Cancer Department
    Full Title: Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer.
    Medical condition: Cisplatin-resistant germ cell cancer of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055103 Testicular cancer metastatic PT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed) DK (Completed) SE (Ongoing) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004039-60 Sponsor Protocol Number: ET13-016 Start Date*: 2014-10-23
    Sponsor Name:CENTRE LEON BERARD
    Full Title: A multicenter study to evaluate a risk-adapted strategy for treatment of extra cranial non seminomateous malignant germ cell tumour in children, adolescent and young adult
    Medical condition: extra cranial non seminomateous malignant germ cell tumour in child, adolescent and young adult
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10049516 Malignant tumor LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004910-33 Sponsor Protocol Number: PAZOTEST-01 Start Date*: 2012-12-24
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of single-agent Pazopanib (Votrient) for patients with relapsed or refractory germ-cell tumors (GCT).
    Medical condition: Testicular or extragonadal germ cell tumors.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10018187 Genitourinary neoplasms malignancy and gender unspecified HLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001688-35 Sponsor Protocol Number: APACHE Start Date*: 2016-09-09
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors
    Medical condition: Advanced and relapsed germ cell tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068971 Germ cell cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 07:59:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA